Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

StriVectin Revises Ad With NAD-Approved ‘Clear And Conspicuous’ Disclosure

Executive Summary

The National Advertising Division continues work by the FTC in 2014 to crack down on inadequate disclosures, inquiring into a disclaimer used in print advertising for StriVectin Intensive Illuminating Serum. The skin-care firm will use a revised ad going forward that addresses NAD’s concerns about the disclaimer’s placement, clarity and conspicuousness.

Advertisement

Related Content

GSK Overly Squeamish About Crest Sensi-Stop Strips Claims – NAD
Will Cosmeceutical Pioneer Turn Its Wagons Around? FDA Warns Strivectin
FTC: All Advertisers Should Heed Lessons From “Operation Full Disclosure”
Advertisement
UsernamePublicRestriction

Register

RS019465

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel